Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor.

被引：0
|
作者：
Yamakawa, Hiroko [1 ]
Mizutani, Akio [1 ]
Arikawa, Yasuyoshi [1 ]
Ebara, Shunsuke [1 ]
Satoh, Yoshihiko [1 ]
Morishita, Daisuke [1 ]
机构：
[1] Chordia Therapeut Inc, Fujisawa, Japan
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5485
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
    Yamakawa, Hiroko
    Mizutani, Akio
    Arikawa, Yasuyoshi
    Ebara, Shunsuke
    Satoh, Yoshihiko
    Morishita, Daisuke
    CANCER SCIENCE, 2023, 114 : 831 - 831
  • [2] Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13
    Chang, Yu
    Yang, Jianzhang
    Tien, Jean Ching-Yi
    Wang, Zhen
    Zhou, Yang
    Zhang, Pujuan
    Huang, Weixue
    Vo, Josh
    Apel, Ingrid J.
    Wang, Cynthia
    Zeng, Victoria Zhixuan
    Cheng, Yunhui
    Li, Shuqin
    Wang, George Xiaoju
    Ding, Ke
    Chinnaiyan, Arul M.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
    Yang, Jianzhang
    Chang, Yu
    Tien, Jean Ching-Yi
    Wang, Zhen
    Zhou, Yang
    Zhang, Pujuan
    Huang, Weixue
    Vo, Josh
    Apel, Ingrid J.
    Wang, Cynthia
    Zeng, Victoria Zhixuan
    Cheng, Yunhui
    Wang, George Xiaoju
    Chinnaiyan, Arul M.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (16) : 11066 - 11083
  • [4] Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model
    Poddutoori, Ramulu
    Rajagopalan, Sujatha
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Sivakumar, Sasirekha
    Nayak, Shilpa S.
    Ravindra, M., V
    Murtuza, Hadianawala
    Devaraja, T. S.
    Kondela, Srinivas
    Tgore, Suraj
    Dhudashiya, Amit A.
    Charamanna, K. B.
    Antony, Thomas
    Daginakatte, Girish
    Giri, Sanjeev
    Chelur, Shekar
    Ramachandra, Murali
    Pandit, Chetan
    Samajdar, Susanta
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition
    Yang, Jianzhang
    Chang, Yu
    Zhou, Kaijie
    Huang, Weixue
    Tien, Jean Ching-Yi
    Zhang, Pujuan
    Liu, Wenyan
    Zhou, Licheng
    Zhou, Yang
    Ren, Xiaomei
    Mannan, Rahul
    Mahapatra, Somnath
    Zhang, Yuping
    Hamadeh, Rudana
    Ervine, Grafton
    Wang, Zhen
    Wang, George Xiaoju
    Chinnaiyan, Arul M.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (06) : 6718 - 6734
  • [6] Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor.
    Peng, Sheng-Bin
    Si, Chong
    Zhang, Youyan
    Van Horn, Robert D.
    Lin, Xi
    Gong, Xueqian
    Huber, Lysiane
    Donoho, Gregory
    Curtis, Carmen
    Strelow, John M.
    Bocchinfuso, Wayne P.
    Guo, Deqi
    Boulet, Serge L.
    Barda, David
    Manglicmot, Danalyn
    Saflor, Melbert-Brian D.
    Wang, Jing
    Xiao, Junpeng
    Chalmers, Michael J.
    Burns, Lee
    Linder, Ryan J.
    Ackermann, Bradley L.
    Cornwell, Paul D.
    Zhou, Lian
    McCann, Denis
    Henry, James
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Discovery and evaluation of ISM6466A, a novel covalent CDK12 inhibitor for the treatment of cancer
    Min, Lihua
    Lu, Hongfu
    Zhang, Yihong
    Wu, Jianping
    Cai, Xin
    Zheng, Min
    Cui, Hui
    Qiao, Junwen
    Ding, Xiao
    Rao, Sujata
    Ren, Feng
    Zhavoronkov, Alex
    CANCER RESEARCH, 2023, 83 (07)
  • [8] Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor
    Li, Qi
    Xing, Shuaishuai
    Chen, Ying
    Liao, Qinghong
    Xiong, Baichen
    He, Siyu
    Lu, Weixuan
    Liu, Yang
    Yang, Hongyu
    Li, Qihang
    Feng, Feng
    Liu, Wenyuan
    Chen, Yao
    Sun, Haopeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 10030 - 10044
  • [9] Potent selective and orally bioavailable inhibition of CDK12 by novel covalent inhibitors
    Poddutoori, Ramulu
    Rajagopalan, Sujatha
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Kasturi, Venkateswarlu
    Sivakumar, Sasirekha
    Nayak, Shilpa
    Ravindra, M., V
    Tgore, Suraj
    Dhudashiya, Amit
    Charamanna, K. B.
    Antony, Thomas
    Mahaboobi, M.
    Giri, Sanjeev
    Daginakatte, Girish C.
    Chelur, Shekar
    Ramachandra, Murali
    Pandit, Chetan
    Samajdar, Susanta
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Discovery and resistance mechanism of a selective CDK12 degrader
    Jiang, Baishan
    Gao, Yang
    Che, Jianwei
    Lu, Wenchao
    Kaltheuner, Ines H.
    Dries, Ruben
    Kalocsay, Marian
    Berberich, Matthew J.
    Jiang, Jie
    You, Inchul
    Kwiatkowski, Nicholas
    Riching, Kristin M.
    Daniels, Danette L.
    Sorger, Peter K.
    Geyer, Matthias
    Zhang, Tinghu
    Gray, Nathanael S.
    NATURE CHEMICAL BIOLOGY, 2021, 17 (06) : 675 - 683
12345